Publications
269
Citations
8,648
Est. group size
~27
Recurring co-author estimate
Active years
43
Publishing since 1984
Kari Kendra's research focuses on clinical trials for melanoma, particularly testing immune-based treatments (such as anti-PD-1 and anti-CTLA-4 checkpoint inhibitors) and targeted drug combinations (like BRAF and MEK inhibitors) in patients with advanced or high-risk skin cancer. This work involves large multi-site cooperative group trials (e.g., SWOG studies) examining how, when, and in what sequence these therapies should be given, as well as analyzing tumor biopsies to understand why some patients respond better than others.
Publication output grew steadily from 2017 through a peak in 2023, with a recent decline in 2024-2026 that likely reflects incomplete indexing of the newest publication years rather than an actual slowdown.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial
Nature Cancer · 2026
- Abstract B038: Inflammatory spatial niches distinguished by antigen presentation and interferon response programs explain the high immune response rate of desmoplastic melanoma: Comparison of biopsies from SWOG S1512 and S1616
Cancer Immunology Research · 2026
- Abstract LB-B005: No effect of the time-of-day infusion of adjuvant pembrolizumab in the outcomes of patients with resectable melanoma in the NCI/SWOG trial S1404
Cancer Immunology Research · 2026
- Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1
Cancer Discovery · 2026
- Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti–PD-1 Therapy
JCO Oncology Practice · 2026
- Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial
Nature Medicine · 2025
- 1601O 3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801
Annals of Oncology · 2025
- DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM)—Final clinical results.
Journal of Clinical Oncology · 2025
- Abstract PR006: High melanoma-specific survival in patients with desmoplastic melanoma treated with single agent anti-PD-1 in SWOG S1512
Cancer Immunology Research · 2025
- Gotistobart in combination with pembrolizumab in patients with advanced melanoma who have progressed on PD-1 inhibitors with or without CTLA-4 inhibitors.
Journal of Clinical Oncology · 2025
- A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with <i>BRAF</i>‐mutated cancers
Cancer · 2024
- Abstract 6550: Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma
Cancer Research · 2024
- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
New England Journal of Medicine · 2023
- Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
Nature Medicine · 2023
- LBA48 Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801
Annals of Oncology · 2023
- Journal of Clinical Oncology×39
- Cancer Research×10
- Cancer Immunology Immunotherapy×8
- Journal of the National Comprehensive Cancer Network×7
- Annals of Oncology×7
- Shurui Cai
Medicine · The Ohio State University
- Christin E. Burd
Medicine · The Ohio State University
- Richard C. Wu
Medicine · The Ohio State University
- Jonathan E. Schoenhals
Medicine · The Ohio State University
- Ruple Jairath
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile